~~<i id='7D0B9A94FA'><strike id='7D0B9A94FA'><tt id='7D0B9A94FA'><pre id='7D0B9A94FA'></pre></tt></strike></i>~~

Home» comprehensive» entertainment

entertainment

author：Wikipedia 2025-09-06 06:00:21 Page View：95

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police
Next article： Continuity nursing helped my family in our darkest PICU moments

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Ending racial health disparities hinges on penalties, political will

AdobeThenation’swidespreadracialhealthdisparitieswon’tbeerasedwithoutchangestohowhealthcaresystemsar

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

Indian pharmaceutical industry in denial over drug

AchemistworksatapharmaceuticalmanufacturingplantontheoutskirtsofMumbai.Drugmakersinthecountryhavecom